Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness

World Journal of Urology

Volumn 31, Issue 2, 2013, Pages 359-364

  Ohno, Yoshio ^a   Nakashima, Jun ^a   Izumi, Miki ^a   Ohori, Makoto ^a   Hashimoto, Takeshi ^a   Tachibana, Masaaki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biochemical recurrence; Legumain; Prognostic factor; Prostate cancer

Indexed keywords

EID: 84876432021     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0977-z     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Boorjian SA, Eastham JA, Graefen M et al (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61: 664-675.
3. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147-1154.
4. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995-2005.
5. Ishii S (1994) Legumain: asparaginyl endopeptidase. Methods Enzymol 244: 604-615.
6. Shirahama-Noda K, Yamamoto A, Sugihara K et al (2003) Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 278: 33194-33199.
7. Murthy RV, Arbman G, Gao J et al (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res 11: 2293-2299.
8. Gawenda J, Traub F, Luck HJ et al (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat 102: 1-6.
9. Liu C, Sun C, Huang H et al (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 63: 2957-2964.
10. Sobel RE, Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines-Part 1. J Urol 173: 342-359.
11. Thalmann GN, Sikes RA, Wu TT et al (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44: 91-103.
12. Greene FL, Page DL, Fleming ID (2002) AJCC cancer staging manual, 6th edn. Springer, New York.
13. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583.
14. Choi SJ, Reddy SV, Devlin RD et al (1999) Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption. J Biol Chem 274: 27747-27753.
15. Manoury B, Hewitt EW, Morrice N et al (1998) An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 396: 695-699.
16. Morita Y, Araki H, Sugimoto T et al (2007) Legumain/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett 581: 1417-1424.
17. Choi SJ, Kurihara N, Oba Y et al (2001) Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J Bone Miner Res 16: 1804-1811.
18. Wang L, Chen S, Zhang M et al (2012) Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem doi: 10. 1002/jcb. 23143. [Epub ahead of print].
19. Wu W, Luo Y, Sun C et al (2006) Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66: 970-980.
20. Stern L, Perry R, Ofek P et al (2009) A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjug Chem 20: 500-510.
21. Bajjuri KM, Liu Y, Liu C et al (2011) The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity. Chem Med Chem 6: 54-59.
22. Lewen S, Zhou H, Hu HD et al (2008) A legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 57: 507-515.
23. Luo Y, Zhou H, Krueger J et al (2006) Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132-2141.
24. Lopergolo A, Zaffaroni N (2009) Biomolecular markers of outcome prediction in prostate cancer. Cancer 115: 3058-3067.
25. Darnel AD, Behmoaram E, Vollmer RT et al (2009) Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res 15: 1376-1383.
26. Miyamoto H, Hernandez DJ, Epstein JI (2009) A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. Hum Pathol 40: 1693-1698.
27. Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71: 281-288.